Immutep’s phase III TACTI-004 study of eftilagimod alfa (efti) in first‑line non‑small‑cell lung cancer was halted after an independent data monitoring committee recommended stopping for futility. The decision prompted a near‑term collapse in Immutep’s share price and immediate wind‑down activity around the program. The trial tested efti in combination with pembrolizumab (Keytruda) across an international cohort. Company leadership said it was "very disappointed and surprised" by the outcome and initiated a comprehensive review of the available data to understand the futility signal and determine next steps. Analysts and investors were caught off guard given prior positive signals in smaller cohorts; the result raises questions about translating earlier-phase immunotherapy signals into large, randomized settings.